<\/b><\/p>\n
<\/b><\/p>\n
TUESDAY, Sept. 17, 2019 (HealthDay News) — Hospital-level high-risk antibiotic use is associated with the risk for hospital-associated (HA) Clostridioides difficile<\/i> infection (CDI), according to a study published online Sept. 16 in Infection Control & Hospital Epidemiology<\/i>.<\/p>\n
Ying P. Tabak, Ph.D., from Becton, Dickinson and Co., in Franklin Lakes, New Jersey, and colleagues analyzed 2016 to 2017 data from 171 hospitals to assess previously defined high-risk antibiotic use in relation to CDIs. Second-, third-, and fourth-generation cephalosporins, fluoroquinolones, carbapenems, and lincosamides were included as high-risk antibiotics.<\/p>\n
The researchers found that per 1,000 days present, the median days of therapy for high-risk antibiotic use were 241.2; per 10,000 admissions, the overall HA CDI rate was 33. High-risk antibiotic use was associated with HA CDI (correlation coefficient, 0.22), with a higher correlation in teaching hospitals (correlation coefficient, 0.38). After adjustment for confounders, for every 100-day increase in high-risk antibiotic therapy per 1,000 days present, the risk for HA CDI increased 12 percent (relative risk, 1.12).<\/p>\n
“This highlights the importance of ongoing monitoring of antibiotic use in hospitals for patient safety as it relates to the effect of antibiotics on C. difficile<\/i> infections,” coauthor L. Clifford McDonald, M.D., medical epidemiologist at the U.S. Centers for Disease Control and Prevention, said in a statement. “In the future it will also be important to look at the effect of antibiotic use on both C. difficile<\/i> infection and antibiotic resistance simultaneously, rather than examining each piece as separate endeavors.”<\/p>\n
Several authors are employees of Nabriva Therapeutics, which provided funding to the BD Insights Research Team of Becton, Dickinson and Co.<\/p>\n
Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n